Why guessing your supplement needs is costing you

Spend an hour in any health-food shop and you will leave with a bag full of capsules, powders, and optimistic promises. Many people do exactly that — assembling a supplement stack based on a podcast recommendation, a friend's enthusiasm, or the suspicion that persistent tiredness probably means something is low. The monthly spend can easily reach £80 or more. The energy levels, more often than not, stay stubbornly flat.

The problem is not commitment — it is data. A generic multivitamin may deliver far more of certain nutrients than the body can use while missing the specific shortfall that is actually slowing recovery. Some combinations make things worse: calcium and iron taken together can reduce the absorption of both.

Professor Paul Lee's Regeneration by Design names this territory precisely. Chemistry — one of four interdependent pillars in his framework — covers nutrition, hormones, inflammation, and the entire internal biochemical environment. It is a system with its own logic, and right now most people are adjusting it without ever having looked at the dial.

So what does your body actually need?

What a regeneration-focused blood panel actually measures

Thirty-two biomarkers, drawn at Harley Street and reviewed by a physician within five days. That is the Regen Blood Panel — and its structure is worth examining, because the choice of markers is itself an argument about what a regeneration-focused baseline should actually cover.

The panel maps across six categories. Inflammation: hs-CRP, the most sensitive indicator of systemic low-grade inflammation, which longevity research links consistently to accelerated biological ageing. Metabolic function: HOMA-IR, a measure of insulin sensitivity that standard GP screens routinely omit. Hormonal status: the endocrine signals that govern energy output, recovery rate, and tissue repair. Cellular energy markers: the upstream indicators of how efficiently the body is producing and using fuel. Cardiovascular: ApoB and Lp(a), which offer a more precise picture of arterial risk than total cholesterol alone. And liver and renal function: the clearance systems through which any nutritional strategy must pass.

None of these is selected to screen for disease. The panel is a wellness-optimisation baseline — a precise snapshot of the internal biochemical environment at a specific point in time, so that any intervention has a known starting position rather than a plausible guess. The inclusion of hs-CRP, homocysteine, ApoB, and HbA1c is deliberate: these are the markers longevity medicine returns to repeatedly, with retesting every three to six months recommended to track whether lifestyle and nutritional changes are genuinely shifting the biology.

That longitudinal picture is why the panel pairs logically with MAI Motion — Regen PhD's markerless 3D movement capture. Blood chemistry reveals the state of the internal environment; movement analysis shows how the body is expressing that biology under physical load. In Professor Paul Lee's framework, these two signals are inseparable, which is why together they form the Complete Scan: a joint baseline covering what the body is doing inside and how it is performing outside. From that foundation, the Regen365 IV nutrient programme follows a coherent rationale — bypassing gastrointestinal absorption is only a meaningful clinical advantage once you know with precision what the body is actually short of.

Why 'normal' results can still hide functional gaps

There's a gap between 'not flagged' and 'functioning well' — and most blood tests are designed only to catch the former.

Standard lab reference ranges are built from population averages. They mark the boundary below which a result triggers clinical concern, not the threshold at which the body is performing at its ceiling. A vitamin D result that clears the deficiency cut-off does not confirm the body has what it needs for immune resilience and tissue repair. Within-range means the alarm hasn't sounded — it does not mean the signal is strong.

This distinction becomes striking when you examine the approach developed by physician Kaneko, who built a pattern-recognition method from a dataset of more than 350,000 blood results. Rather than asking whether each marker was flagged, Kaneko mapped configurations within the normal range that consistently pointed to individual nutrient insufficiencies. Two examples are particularly concrete: when ALP (alkaline phosphatase) sits persistently low in the absence of liver or bone disease, the pattern may suggest zinc insufficiency. When AST runs consistently higher than ALT, it can signal a shortfall in vitamin B6.

In one well-designed clinical study applying this approach (PMC8538692, 2021), 253 patients with pre-disease states or unresolved chronic symptoms received personalised nutritional therapy guided by these blood-data patterns. No pharmaceutical intervention was used, and the majority recovered from their symptoms — a result that is modest in scope but pointed in its implication: the information needed to act was already present in the data. It simply required a different method of reading it.

That reframing — from disease detection to function optimisation — is exactly what the test-first principle rests on. A panel does not need to return a clinical abnormality to be actionable. The relevant question shifts from 'is anything wrong?' to 'what does the pattern suggest this individual may be missing?' In Regeneration by Design, Professor Paul Lee identifies this active calibration of the internal biochemical environment as the work of the Chemistry pillar: not the absence of illness, but the conditions in which the body genuinely performs.

What your DNA adds — and what it can't tell you alone

A genetic blueprint and a live blood reading are answering different questions. Your DNA reveals structural predispositions — tendencies encoded at birth that remain constant across a lifetime. Your blood panel reveals the terrain as it exists right now: what is being produced, converted, cleared, and depleted. Both are informative; neither is sufficient on its own.

The clearest teaching case in nutrigenomics is the MTHFR variant. Carriers of this polymorphism have a reduced ability to convert dietary or synthetic folate into its biologically active form, 5-MTHF — an enzyme bottleneck that can impair methylation and allow homocysteine to accumulate. The practical implication is meaningful: where most people can use standard folic acid, MTHFR carriers may be better served by L-methylfolate and methylcobalamin, which bypass the conversion step entirely. But knowing you carry the variant does not confirm the predisposition is expressing. A blood homocysteine measurement is still required to see whether the biochemistry has actually shifted — the gene points to a risk; the panel tells you whether that risk is live.

A 2026 Frontiers review adds a necessary caution: the effects of folate supplementation are not linear. They are frequently U-shaped and timing-dependent, meaning overshooting with even the 'right' form carries its own risks. This applies broadly — other variants studied in nutrigenomics, including VDR (vitamin D receptor sensitivity) and CYP1A2 (caffeine metabolism), indicate predispositions rather than certainties, and consumer-grade test quality remains variable. As Singar et al. (2024, PMC11357412) note, methodological heterogeneity in the field means the evidence base is growing rapidly but is not yet definitive.

In Practical Regeneration, Professor Paul Lee is explicit on this point: genetic testing 'can offer context, but is not a prerequisite for progress.' Think of it as a structural map — useful for anticipating the landscape, but not a substitute for knowing where you actually are. The blood panel provides that live coordinate.

The retest loop — where Chemistry meets Time

Chemistry tells you where you are; Time tells you whether you're moving.

A single blood panel, however detailed, is a coordinate — not a trajectory. The Time pillar in Regeneration by Design makes this explicit: monitoring and repair windows are not administrative afterthoughts but active mechanisms. What separates a personalised protocol from an expensive habit is whether you measure its effect.

The cautionary case is vitamin D. The large-scale VITAL trial found that supplementing already-replete individuals with high-dose D3 produced no measurable benefit. Without a baseline, there is no way to know whether a given supplement is filling a real gap or simply circulating unused. Well-intentioned does not mean well-targeted.

The Regen PhD Optimise programme closes this loop in practice: the Complete Scan baseline feeds into a calibrated Regen365 IV protocol, with quarterly biomarker reviews built in. At each check, markers including hs-CRP, homocysteine, ApoB, and HbA1c are re-measured — not to confirm the supplement is being taken, but to confirm the chemistry is responding.

Professor Paul Lee's Digital Body Bank concept extends the principle further. Longitudinal biomarker data becomes a personal asset — a record of how your internal environment has shifted across months and years, available as a reference whenever a course-correction is needed. Captured at 55, it becomes the benchmark against which 60 is measured.

Practical rhythm: test, intervene, retest at three months.

Designing your chemistry — a practical starting point

Before adding anything to the chemistry, know what it already contains.

That single principle generates the practical sequence. A comprehensive blood panel — covering inflammation, metabolic, hormonal, cellular energy, and cardiovascular markers — establishes where the internal environment actually sits, independent of what you expect it to show. DNA insights then add a layer of structural context: which supplement forms the body handles most efficiently, which markers warrant closest attention, and where conversion bottlenecks are likely. With both in hand, intervention becomes a targeted act — matching form, dose, and timing to the combined picture rather than to a population-average RDA.

The temptation is to skip directly to step three. The supplement market does not reward patience; it rewards volume. But as Professor Paul Lee argues in Regeneration by Design, Chemistry is not about accumulation — it is about understanding what the internal environment needs and delivering it with precision. The panel removes the uncertainty that turns supplementation into expenditure rather than investment.

For those who want this managed end-to-end, Regen PhD's Complete Scan and Optimise programme applies exactly this workflow: baseline, targeted intervention, quarterly biomarker review. The same sequence holds when working independently.

On the economics: a single comprehensive blood panel typically costs less than three months of unguided supplementation. That is the honest case for testing first — not sophistication, but efficiency.